Original Research

Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/HER2– advanced or metastatic breast cancer in Spain

Galve-Calvo E, González-Haba E, Gostkorzewicz J, Martínez I, Pérez-Mitru A

ClinicoEconomics and Outcomes Research 2018, 10:773-790

Published Date: 14 November 2018